Researchers Uncover Cell Fusion Mechanism

October 8, 2006

In a study that could shed light on disorders that occur in skeletal muscles, bone, the placenta, and other organs where fused cells are common, researchers at the Technion-Israel Institute of Technology and at the US National Institute of Child Health and Human Development have identified a protein in worms that encourages two or more normal-sized cells to fuse into a single giant cell with multiple nuclei—a normal but little understood phenomenon in biology. The study is published in the October 2 issue of the journal Developmental Cell.

The findings could aid researchers looking for ways to fuse therapeutic stem cells or cells carrying replacement genetic parts to cells that are damaged or diseased, according to lead researchers Professor Benjamin Podbilewicz of the Technion and Leonid V. Chernomordik of the NICHD.

“If you could deliver a necessary protein or gene to diseased muscle cells by fusing cells that carry this gene, in theory you could use this technique to fix these muscles,” said Podbilewicz.

Although researchers previously uncovered fusion proteins that help viruses latch on to their target cells and proteins that promote fusion between cells, the study by the combined Technion-NICHD team is one of the first to identify a protein that drives fusion between cells in normal animal and plant development.

Podbilewicz and colleagues first identified a cell membrane protein called EFF-1 as a possible fusion protein in their studies of the nematode worm C. elegans. In the skin of worms with mutated EFF-1, “where most fusion takes place in C. elegans, cells sort of get lost, and start making very funny structures,” Podbilewicz explained.

To clarify EFF-1’s cellular role, the researchers inserted the protein in insect cells grown in the lab. They quickly discovered that EFF-1 encourages cells to fuse together, forming giant cells with more than one cell nucleus. The cell nucleus contains a cell’s genes wrapped up in chromosomes.

Both cells must contain EFF-1 to fuse together, the researchers found. Cell fusion aided by EFF-1 also includes a “half-fused” step where the cell membranes blend together but the contents of each cell do not mingle. This half-fusion step is a trait shared by viral fusion and fusion inside cells.

The finding could help researchers understand the development of some important organs in humans. “One of the biggest examples—one third of all our body weight—is the long fibers of our skeletal muscles, which form by cell fusion,” Podbilewicz said.

In theory, researchers could also try to harness the natural mechanisms of cell fusion to deliver cell therapies—by fusing regenerative stem cells to diseased cells, for instance.

But Podbilewicz warned that giant cells with multiple nuclei have also been found in certain types of cancer. “If cells fuse, they will get more chromosomes than usual, and more chromosomes than usual can cause defects” in diseases such as cancer, he said.

So far, researchers have not found a human equivalent of EFF-1. Podbilewicz said researchers would have to search for the human version by looking for proteins that have a structure similar to that of EFF-1, since the DNA sequence that encodes the fusion protein is probably quite different between worms and humans.

The study authors included Evgenia Leikina of the NICHD and Amir Sapir, Clari Valansi, Meital Suissa and Gidi Shemer of the Technion-Israel Institute of Technology.

Source: American Technion Society

Explore further: New link seen between gene fusion and bladder cancer

Related Stories

New link seen between gene fusion and bladder cancer

September 18, 2017

(HealthDay)—The fibroblast growth factor receptor 3 (FGFR3) transforming acidic coiled-coil containing protein 3 (TACC3) (FT3) gene fusion recruits endogenous TACC3 away from the mitotic spindle, resulting in errors in ...

When HIV drugs don't cooperate

October 2, 2017

The term "synergy" has gained a reputation as an overused buzzword, but it has a quantifiable definition in pharmacology. Two drugs are considered synergistic when their effectiveness when used together is greater than the ...

Two agents deliver knockout punches to Ewing sarcoma

October 3, 2017

When combined with an already FDA-approved chemotherapy, a novel agent developed by researchers at Georgetown Lombardi Comprehensive Cancer Center, appears to halt the ability of Ewing sarcoma to grow and progress.

New approaches in targeted cancer therapy

September 26, 2017

Precision medicine, which custom-tailors therapies to the needs of individual patients, is becoming more and more important in cancer therapy. Today, molecular-biological diagnostics can precisely identify alterations in ...

Fatal glandular cancer will soon be possible to treat

September 28, 2017

A new combination of existing drugs has been shown to block the cancer gene behind a fatal form of glandular cancer, adenoid cystic carcinoma. The findings from the Sahlgrenska Academy can lead to new treatment for patients ...

Recommended for you

Two teams independently test Tomonaga–Luttinger theory

October 20, 2017

(Phys.org)—Two teams of researchers working independently of one another have found ways to test aspects of the Tomonaga–Luttinger theory that describes interacting quantum particles in 1-D ensembles in a Tomonaga–Luttinger ...

Dawn mission extended at Ceres

October 20, 2017

NASA has authorized a second extension of the Dawn mission at Ceres, the largest object in the asteroid belt between Mars and Jupiter. During this extension, the spacecraft will descend to lower altitudes than ever before ...

Close up view of growing polymer chain show jump steps

October 20, 2017

(Phys.org)—A team of researchers at Cornell University has devised a means for watching as a polymer chain grows after application of a catalyst. In their paper published in the journal Science, the team explains how they ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.